doi:10.3969/j.issn.1674-5817.2018.02.007

[1] Polo V,Besse B.Maintenance strategies in stage IV no-small-cell lung cancer (NSCLC):in which patients,with which drugs?[J].Ann Oncol,2013,25(7):1283-1293.
[2] Domingues D,Turner A,Silva MD,et al.Immunotherapy and lung cancer:current developments and novel targeted therapies[J].Immuotherapy,2014,6(11):1221-1235.
[3] Sher T,Dy GK,Adjei AA.Small cell lung cancer[J].Mayo Clin Proc,2008,83(3):355-367.
[4] Molina JR,Yang P,Cassivi SD,et al.Non-small cell lung cancer:epidemiology,risk factors,treatment,and survivorship[J].Mayo Clin Proc,2008,83(5):584-594.
[5] Chen W,He J.Annual report on status of Cancer in China[J].Chin J Cancer Res,2015,27(1):2-12.
[6] McNeill RS,Vitucci M,Wu J,et al.Contemporary murine models in preclinical astrocytoma drug development[J].Neuro Oncol,2015,17(1):12-28.
[7] Fiebig HH,Neumann HA,Henss H,et al.Development of three human small cell lung cancer models in nude mice[J].Recent Results Cancer Res,1985,97:77-86.
[8] Houghton A,Houghton PJ,Green AA.Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice[J].Cancer Res,1982,42(2):535-539.
[9] Sia D,Moeini A,Labgaa I,et al.The future of patient-derived tumor xenografts in cancer treatment[J].Pharmacogenomics,2015,16(14):1671-1683.
[10] Tentler JJ,Tan AC,Weekes CD,et al.Patient-derived tumour xenografts as models for oncology drug development[J].Nat Rev Clin Oncol,2012,9(6):338-350.
[11] Siolas D,Hannon GJ.Patient-derived tumor xenografts:transforming clinical samples into mouse models[J].Cancer Res,2013,73(17):5315-5319.
[12] Izumchenko E,Meir J,Bedi A,et al.Patient derived xenografts as tools in pharmaceutical development[J].Clin Pharmacol Ther,2016,99(6):612-621.
[13] Sun S,Zhang Z.Patient-derived xenograft platform of OSCC:a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization[J].Front Med,2016,10(1):104-110.
[14] Gao H,Korn JM,Ferretti S,et al.High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response[J].Nat Med,2015,21(11):1318-1325.
[15] McNeill RS,Vitucci M,Wu J,et al.Contemporary murine models in preclinical astrocytoma drug development[J].Neuro Oncol,2015,17(1):12-28.
[16] Chijiwa T,Kawai K,Noguchi A,et al.Establishment of patient-derived cancer xenografts in immunodeficient NOG mice[J].Int J Oncol,2015,47(1):61-70.
[17] Burchill SA.What do,can and should we learn from models to evaluate potential anticancer agents[J].Future Oncol,2006,2(2):201-211.
[18] Gillet JP,Calcagno AM,Varma S,et al.Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance[J].Proc Natl Acad Sci U S A,2011,108(46):18708-18713.
[19] Choi YY,Lee JE,Kim H,et al.Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer[J].Sci Rep,2016,6:22172.
[20] Pan CX,Zhang H,Tepper CG,et al.Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy[J].PLoS One,2015,10(8):e0134346.
[21] 张鹏,韩一平,黄玲,等.TTF-1和p63在NSCLC组织中的表达及临床意义[J].中国肺癌杂志2009,9,12(9):995-999.
[22] 唐诗聪,潘泓,黄耀元,等.人非小细胞肺癌裸鼠移植瘤模型的建立[J].昆明医科大学学报,2017,38(2):28-32.
[23] Cho SY,Kang W,Han JY,et al.An integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts[J].Mol Cells,2016,39(2):77-86.
[24] Morton JJ,Bird G,Keysar SB,et al.Xact mice:humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer[J].Oncogene,2016,35(3):290-300.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	JIAO Qingzhen, WU Guihua, TANG Wen, FAN Fan, FENG Kai, YANG Chunxiang, QIAO Jian, DENG Sufang. Dynamic Monitoring and Analysis of Ammonia Concentration in Laboratory Animal Facilities Under Suspension of Heating Ventilation and Air Conditioning System [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 490-495.
[2]	LIU Wentao, LUO Yanhong, LONG Yongxia, LUO Qihui, CHEN Zhengli, LIU Lida. Common Environmental Problems and Testing Experiences in Laboratory Animal Facilities in Sichuan Province [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 483-489.
[3]	ZHAO Xin, WANG Chenxi, SHI Wenqing, LOU Yuefen. Advances in the Application of Zebrafish in the Research of Inflammatory Bowel Disease Mechanisms and Drug Development [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 422-431.
[4]	GONG Leilei, WANG Xiaoxia, FENG Xuewei, LI Xinlei, ZHAO Han, ZHANG Xueyan, FENG Xin. A Mouse Model and Mechanism Study of Premature Ovarian Insufficiency Induced by Different Concentrations of Cyclophosphamide [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 403-410.
[5]	LIN Zhenhua, CHU Xiangyu, WEI Zhenxi, DONG Chuanjun, ZHAO Zenglin, SUN Xiaoxia, LI Qingyu, ZHANG Qi. Evaluation of the Safety and Efficacy of Bone Cement in Experimental Pigs Using Vertebroplasty [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 466-472.
[6]	JIANG Juan, SONG Ning, LIAN Wenbo, SHAO Congcong, GU Wenwen, SHI Yan. Comparison of Histopathological and Molecular Pathological Phenotypes in Mouse Models of Intrauterine Adhesions Induced by Two Concentrations of Ethanol Perfusion [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 393-402.
[7]	LIU Yueqin, XUE Weiguo, WANG Shuyou, SHEN Yaohua, JIA Shuyong, WANG Guangjun, SONG Xiaojing. Observation of Digestive Tract Tissue Morphology in Mice Using Probe-Based Confocal Laser Endomicroscopy [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 457-465.
[8]	ZHENG Qingyong, YANG Donghua, MA Zhichao, ZHOU Ziyu, LU Yang, WANG Jingyu, XING Lina, KANG Yingying, DU Li, ZHAO Chunxiang, DI Baoshan, TIAN Jinhui. Recommendations for Standardized Reporting of Systematic Reviews and Meta-Analysis of Animal Experiments [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 496-507.
[9]	WANG Tingjun, LUO Hao, CHEN Qi. Discussion on AI-Based Digital Upgrade and Application Practice of Laboratory Animal Centers [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 473-482.
[10]	WANG Jiaoxiang, ZHANG Lu, CHEN Shuhan, JIAO Deling, ZHAO Heng, WEI Taiyun, GUO Jianxiong, XU Kaixiang, WEI Hongjiang. Construction and Functional Validation of GTKO/hCD55 Gene-Edited Xenotransplant Donor Pigs [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 379-392.
[11]	QIN Chao, LI Shuangxing, ZHAO Tingting, JIANG Chenchen, ZHAO Jing, YANG Yanwei, LIN Zhi, WANG Sanlong, WEN Hairuo. Study on the 90-day Feeding Experimental Background Data of SD Rats for Drug Safety Evaluation [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 439-448.
[12]	LIU Kun, LAN Qing, YI Bing, XIE Xiaojie. Key Challenges and Mitigation Strategies for Animal Pregnancy in Non-clinical Reproductive Toxicity Testing of Drugs [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 449-456.
[13]	. [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 508-514.
[14]	CHEN Ziyi, SUN Hongyan, KANG Pinfang, WU Wenjuan. Research Advances in Animal Experimental Models of Pulmonary Hypertension [J]. Laboratory Animal and Comparative Medicine, 2025, (): 1-12.
[15]	XU Yingtao, WANG Mengmeng, LIN Ping, CHI Haitao, WANG Yi, BAI Ying. Exosomes Improve Ischemic Stroke by Regulation of Ferroptosis Through the NRF2/SLC7A11/GPX4 Pathway in Mice [J]. Laboratory Animal and Comparative Medicine, 2025, (): 1-11.